A Study That Finally Tests the Question Nobody Had Numbers For
Every show season, the same small ritual repeats itself in hundreds of hunter and jumper barns: a tube of omeprazole goes back on the feed room order, refilled on a schedule that has less to do with a diagnosis than with habit. The drug has earned that trust. It treats equine gastric ulcer syndrome more reliably than anything that came before it, and for nearly three decades the working assumption inside the sport has been that a horse on omeprazole is a horse protected, with essentially nothing on the other side of the ledger.
A new study out of the Hong Kong Jockey Club complicates that assumption. It does not overturn it. Published online this month in the Journal of the American Veterinary Medical Association, the retrospective cohort study examined 2,924 Thoroughbred racehorses in training during the 2012 to 2013 and 2022 to 2023 racing seasons. Lead author Olivia J. Jones and colleagues in the Jockey Club's Department of Veterinary Clinical Sciences found that for every additional 10 grams of omeprazole a horse received in the preceding 30 days, the hazard of a veterinarian detecting exercise-induced pulmonary hemorrhage after a race rose by roughly 8 percent (hazard ratio 1.08, 95 percent confidence interval 1.01 to 1.15). Visible nosebleed, the rarer and more severe marker of the same bleeding, trended in the same direction but narrowly missed statistical significance. Fractures and atrial fibrillation, the two other outcomes the researchers checked, showed no relationship to omeprazole exposure at all, which argues against the simplest alternative explanation: that horses getting more omeprazole were just generally sicker or more heavily raced. The authors calculated that, if the relationship is causal, roughly 11 percent of the bleeding cases in their population could be attributed to the drug. They looked for a cumulative dose low enough to sit clear of that association. They did not find one.
The Question the Sport's Own Ethicists Left Unanswered
This is not the first time researchers have asked whether competition horses are dosed with omeprazole more by habit than by indication. In 2024, veterinary ethicist Madeleine Campbell of the University of Nottingham and gastric ulcer specialist Benjamin Sykes of Massey University published an ethico-legal review in the Equine Veterinary Journal asking whether governing bodies should even allow omeprazole on the day of competition. Their answer favored welfare over appearances. If a horse is already being treated outside competition, which most are, then withholding the drug on show day for the sake of looking "clean" causes needless discomfort for no real benefit, and the rules ought to say so.
Campbell and Sykes were careful, though, to flag what their own argument did not cover. Their paper states plainly that the analysis did not consider the possible health effects of the out-of-competition treatment that makes the welfare case work in the first place. It assumed that chronic use was the safe, settled part of the equation and competition-day use was the contested part. Two years later, the Hong Kong Jockey Club data are among the first real evidence to test that assumption directly, and the first finding is not reassurance. It is a dose-response signal nobody had previously quantified.
The Case the Numbers Still Support
Untreated ulcers are not a trivial alternative to weigh against this. A 2019 gastroscopy study of 40 high-level jumping horses in Brazil, published in the Arquivo Brasileiro de Medicina Veterinaria e Zootecnia, found squamous ulcers in 42.5 percent of the horses examined, whether they were in full training or coming off a month of rest. That figure sits inside a published range for performance horses generally running from under a fifth to nearly all of them, depending on discipline and how carefully anyone scopes for it. For an owner weighing whether to treat, the welfare cost of doing nothing is not hypothetical.
Sykes has summed up the drug's overall record this way: "Omeprazole has a high safety profile, but that does not mean omeprazole is universally safe." The new bleeding signal does not contradict that framing. It is a modest, dose-dependent association drawn from a single retrospective cohort of Thoroughbreds galloping at speeds no hunter or jumper reaches, built from observational data that cannot rule out some unmeasured reason harder-working horses both bleed more and get dosed more. It says nothing about fracture risk or heart rhythm. And it was not measured in English sport horses at all, only in racehorses in Hong Kong, which leaves the honest answer for hunters and jumpers specifically as: unknown.
What the Pharmacology Already Knew
The rest of the record is more settled, and some of it cuts the other way entirely. A 2023 trial from the Massey University group gave 14 retired Thoroughbred racehorses a clinical 57-day course of oral omeprazole and tracked serum gastrin, the hormone acid suppression leaves with nowhere to go. Gastrin rose roughly two and a half times its baseline by the first week, plateaued rather than climbing further, and returned to normal within two to four days once the drug stopped. The same research team concluded their data did not support the common practice of tapering a horse off omeprazole gradually, the opposite of what a rebound-acid story would predict.
A smaller, earlier study from Kentucky Equine Research found a different mechanical cost. In four Thoroughbred geldings, omeprazole measurably reduced how much dietary calcium each horse actually absorbed, by roughly ten to fifteen percentage points depending on the calcium source in the feed. The sample was too small to generalize with confidence, and the researchers noted that most commercial feeds already carry enough calcium margin to absorb that loss. But it is one more data point against the idea that this drug interacts with nothing else happening in the horse's body.
2,924 Thoroughbred racehorses studied in Hong Kong, 2012 to 2013 and 2022 to 2023 seasons
Each extra 10 grams of omeprazole in 30 days: 8 percent higher hazard of detected bleeding
No cumulative dose was identified as clear of the association
No link found to fracture or atrial fibrillation
Gastrin rises during treatment but resolves within 2 to 4 days of stopping, no taper needed
42.5 percent of jumping horses in a Brazilian study had ulcers regardless of training status
Autopilot Was Always the Weaker Argument
None of this is a reason to pull a diagnosed ulcer patient off treatment, and nothing here should be read that way. What it adds up to is a reason to stop treating the prescription as something that renews itself. A horse that scoped positive for gastric disease in March and has been on the same dose every show weekend since, without anyone looking again, has slipped from treatment into habit, and the Hong Kong data are the first real evidence that the habit carries a cost, even if nobody yet knows how to price that cost for a hunter instead of a racehorse.
The more defensible version of prophylactic omeprazole looks less like a standing refill and more like any other prescription: a scope or a clinical picture that justifies starting it, a defined course, and a point in the season when somebody checks whether the horse still needs it. For more on recognizing and managing the disease omeprazole exists to treat, see our guide to equine gastric ulcers. The drug has earned its place in the kit. It has not earned a permanent, unexamined one.
1 Kommentar
This is a prime example of a misleading headline, not to mention inappropriate conclusions from a study. Firstly, the study was done in race horses, not show horses. Secondly, the study was a retrospective, not a blinded prospective, study. Thirdly, if all you look at the associations that were found, you might then determine that a cause and effect relationship was uncovered. But wait a minute, does it really make sense that omeprazole in itself exacerbates EIPH? No! What does exacerbate EIPH then. Many things, of course, and mostly EXERCISE. My guess, and it is just that, is that the horses given more omeprazole were trained harder. Or, more likely, the horses that were trained harder were given more omeprazole, with the thinking being that the more intensive training would impose a greater ulcerogenic stimulus.
Retrospective studies looking for associations are like throwing mud on the wall and seeing what sticks. They are useful for identifying potential associations, but they are just the beginning of uncovering what is really going on.